Data from the UK’s National Health Service EndoBarrier Service show a significant reduction in HbA1c, weight, liver fat, and cardiovascular disease risks as well as a reduction in the need for insulin in some patients.
Alcon paid $285 million to acquire PowerVision, a company developing fluid-based intraocular lens implants.
The Abbott Park, IL-based company’s expanded indication would allow the MitraClip to address the secondary form of mitral regurgitation and would significantly increase the amount of people with MR able to be treated by the device.
The Kalamazoo, MI-based company is expected to pay $110 million up front, plus an additional $110 million in milestones to pick up OrthoSpace.
A new technology can diagnose a suspicious lesion in breast tissue in a third of a second, Dune Medical Devices reported.
The company said it is preparing a written response to FDA and has taken steps to remediate the observations made during an FDA inspection last year.
As the Irvine, CA-based company strengthens its mitral valve portfolio, it also faces a lawsuit from Abbott Laboratories over the Pascal system.
Think your startup has what it takes to go head to head with other young companies in medtech? Find out by entering our annual tournament.
The company said it will sell its health information systems business unit to Philips. The deal is expected to close later this year.
Parsippany-Troy Hills, NJ-based Pacira Pharmaceuticals to pay up to $120 million cash up front and an additional $100 million upon the achievement of milestones under the terms of the deal.
The company said the pause in sales was temporary and that it was not related to the performance and safety of Recell.
Influenza and its complications cause as many as 140,000 to 710,000 hospitalizations and 12,000 to 56,000 deaths annually in the U.S.